Two parties have started formal due diligence on Qiagen as part of the molecular diagnostics provider's strategic review, with a sale price of around $50 a share being discussed. The due diligence began last week, according to a CTFN report citing people familiar with the matter, though the parties could still walk away without making an offer and Qiagen could remain standalone. The report follows Qiagen's announcement that Jonathan M. Pratt was appointed CEO effective September 1, and Bloomberg reported that private equity firms EQT AB and KKR & Co. are among those exploring offers. Qiagen CEO Thierry Bernard said in March the company was working with Moelis & Co. and Goldman Sachs to review strategic alternatives.
Goldman Sachs Group Inc
Moelis & Co
Qiagen NVsale process underway with due diligence and price discussion
KKR & Co. Inc.private equity firm exploring offer for Qiagen
EQT Corporation